Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond


Por: Beecker, J, Papp, KA, Dutz, J, Vender, RB, Gniadecki, R, Cooper, C, Gisondi, P, Gooderham, M, Hong, CH, Kirchhof, MG, Lynde, CW, Maari, C, Poulin, Y, Puig, L

Publicada: 1 abr 2021 Ahead of Print: 1 feb 2021
Resumen:
Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2, a novel RNA virus that was declared a global pandemic on 11 March 2020. The efficiency of infection with SARS-CoV-2 is reflected by its rapid global spread. The SARS-CoV-2 pandemic has implications for patients with inflammatory skin diseases on systemic immunotherapy who may be at increased risk of infection or more severe infection. This position paper is a focused examination of current evidence considering the mechanisms of action of immunotherapeutic drugs in relation to immune response to SARS-CoV-2. We aim to provide practical guidance for dermatologists managing patients with inflammatory skin conditions on systemic therapies during the current pandemic and beyond. Considering the limited and rapidly evolving evidence, mechanisms of action of therapies, and current knowledge of SARS-CoV-2 infection, we propose that systemic immunotherapy can be continued, with special considerations for at risk patients or those presenting with symptoms.

Filiaciones:
Beecker, J:
 Univ Ottawa, Ottawa, ON, Canada

 Ottawa Hosp, Div Dermatol, Ottawa, ON, Canada

 Ottawa Hosp Res Inst, Ottawa, ON, Canada

 Prob Med Res Inc, Waterloo, ON, Canada

Papp, KA:
 Prob Med Res Inc, Waterloo, ON, Canada

 K Papp Clin Res, Waterloo, ON, Canada

Dutz, J:
 Skin Care Ctr, Vancouver, BC, Canada

 Univ British Columbia, Dept Dermatol & Skin Sci, Vancouver, BC, Canada

 BC Childrens Hosp Res Inst, Skin Sci, Vancouver, BC, Canada

Vender, RB:
 Dermatrials Res Inc, Hamilton, ON, Canada

 McMaster Univ, Dept Med, Hamilton, ON, Canada

Gniadecki, R:
 Prob Med Res Inc, Waterloo, ON, Canada

 Univ Alberta, Fac Med & Dent, Dept Med, Div Dermatol, Edmonton, AB, Canada

Cooper, C:
 Univ Ottawa, Ottawa, ON, Canada

 Ottawa Hosp Res Inst, Ottawa, ON, Canada

 Ottawa Hosp, Ottawa, ON, Canada

 Reg Hepatitis Program, Ottawa, ON, Canada

Gisondi, P:
 Univ Verona, Dept Med, Sect Dermatol & Venereol, Verona, Italy

Gooderham, M:
 Prob Med Res Inc, Waterloo, ON, Canada

 SKiN Centre Dermatol, Peterborough, ON, Canada

Hong, CH:
 Prob Med Res Inc, Waterloo, ON, Canada

 Univ British Columbia, Dept Dermatol & Skin Sci, Vancouver, BC, Canada

 Dr Chih Ho Hong Med Inc, Surrey, BC, Canada

Kirchhof, MG:
 Univ Ottawa, Ottawa, ON, Canada

 Ottawa Hosp, Div Dermatol, Ottawa, ON, Canada

Lynde, CW:
 Prob Med Res Inc, Waterloo, ON, Canada

 Lynde Inst Dermatol, Markham, ON, Canada

Maari, C:
 Innovaderm Res Inc, Montreal, PQ, Canada

Poulin, Y:
 Ctr Rech Dermatol Quebec Metropolitain, Quebec City, PQ, Canada

 Univ Laval, Dept Med, Hop Hotel Dieu Quebec, Quebec City, PQ, Canada

Puig, L:
 Hosp Santa Creu & Sant Pau, Dept Dermatol, Barcelona, Spain
ISSN: 09269959
Editorial
WILEY, 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Reino Unido
Tipo de documento: Article
Volumen: 35 Número: 4
Páginas: 797-806
WOS Id: 000614222700001
ID de PubMed: 33533553
imagen Bronze, Green Published

MÉTRICAS